New Product Briefs
This article was originally published in The Gray Sheet
Hologic: Company expects to launch its new radiation therapy system by the end of the year, having secured FDA clearance Aug. 27, Hologic announced Sept. 1. MammoSite ML is a multi-lumen version of the firm's original, single-lumen MammoSite system, cleared in 2002. The accelerated partial breast irradiation (APBI) devices provide targeted breast cancer radiation therapy directly to the area where cancer is most likely to recur by inflating a balloon catheter containing radioactive material into the surgical cavity after the tumor is removed. The multi-lumen model allows oncologists to shift the radiation dose to the areas within the cavity that need it most, the firm explains. Hologic obtained the MammoSite technology when it bought Cytyc for $6.2 billion in 2007 (1"The Gray Sheet" May 28, 2007)
You may also be interested in...
St. Jude Medical's Merlin.net Patient Care Network monitoring system now supports all three types of cardiac rhythm management devices, following FDA approval of St. Jude's Accent RF pacemaker and Anthem RF cardiacresynchronization therapy pacemaker (CRT-P)
The combination of mammography device maker Hologic and cervical cancer test firm Cytyc will create a women's health powerhouse with $1.44 billion in combined annual revenues
In this week's podcast edition of Five Must-Know Things: landmark results for lecanemab in Alzheimer’s; other Alzheimer’s players rise after the lecanemab results; Leqvio’s importance to Novartis; Pfizer’s secret sauce for digitalization; and Amgen’s clinical trial diversity efforts.